Patents by Inventor Matthias Stadtfeld

Matthias Stadtfeld has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for making induced pluripotent stem cells
    Patent number: 10443043
    Abstract: In vitro methods for generating induced pluripotent cells (iPSCs) are disclosed herein. Also encompassed are recombinant iPSCs generated using these methods and methods of use thereof.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: October 15, 2019
    Assignee: NEW YORK UNIVERSITY
    Inventors: Matthias Stadtfeld, Simon E. Vidal, Bhishma Amlani
  • METHODS FOR MAKING INDUCED PLURIPOTENT STEM CELLS
    Publication number: 20160326497
    Abstract: In vitro methods for generating induced pluripotent cells (iPSCs) are disclosed herein. Also encompassed are recombinant iPSCs generated using these methods and methods of use thereof.
    Type: Application
    Filed: May 6, 2016
    Publication date: November 10, 2016
    Inventors: Matthias Stadtfeld, Simon E. Vidal, Bhishma Amlani
  • TGF-BETA RECEPTOR INHIBITORS TO ENHANCE DIRECT REPROGRAMMING
    Publication number: 20140120621
    Abstract: In general, iPS cells are produced by delivery of stem cell-associated genes into adult somatic cells (e.g., fibroblasts). Described herein are methods for enhancing the efficiency and rate of induced pluripotent stem cell production by treating somatic cells with a transforming growth factor-beta receptor (TGF?R) inhibitor. Also described herein are iPS cell compositions made according to the methods described herein and iPS cell compositions comprising an iPS cell in an admixture with a TGF?R inhibitor. Further described herein are kits for producing iPS cells using a TGF?R inhibitor.
    Type: Application
    Filed: October 24, 2013
    Publication date: May 1, 2014
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: Konrad Hochedlinger, Matthias Stadtfeld
  • TGF-beta receptor inhibitors to enhance direct reprogramming
    Patent number: 8603818
    Abstract: In general, iPS cells are produced by delivery of stem cell-associated genes into adult somatic cells (e.g., fibroblasts). Described herein are methods for enhancing the efficiency and rate of induced pluripotent stem cell production by treating somatic cells with a transforming growth factor-beta receptor (TGF?R) inhibitor. Also described herein are iPS cell compositions made according to the methods described herein and iPS cell compositions comprising an iPS cell in an admixture with a TGF?R inhibitor. Further described herein are kits for producing iPS cells using a TGF?R inhibitor.
    Type: Grant
    Filed: September 25, 2012
    Date of Patent: December 10, 2013
    Assignee: The General Hospital Corporation
    Inventors: Konrad Hochedlinger, Matthias Stadtfeld
  • METHOD FOR SELECTING AN IPS CELL
    Publication number: 20130196865
    Abstract: This application relates to a method for selecting an induced pluripotent stem cell (iPS), the method comprising: selecting an iPS cell that expresses a gene in the Dlk1-Dio3 cluster from a population of iPS cells. The method further comprises: comparing the gene expression profile determined for an iPS cell with the gene expression profile determined for an embryonic stem cell; identifying a gene that is differentially expressed in the embryonic stem cell as compared to the iPS cell; and selecting the desired iPS cell from a population of iPS cells.
    Type: Application
    Filed: March 3, 2011
    Publication date: August 1, 2013
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: Konrad Hochedlinger, Matthias Stadtfeld
  • TGF-beta receptor inhibitors to enhance direct reprogramming
    Patent number: 8298825
    Abstract: In general, iPS cells are produced by delivery of stem cell-associated genes into adult somatic cells (e.g., fibroblasts). Described herein are methods for enhancing the efficiency and rate of induced pluripotent stem cell production by treating somatic cells with a transforming growth factor-beta receptor (TGF?R) inhibitor. Also described herein are iPS cell compositions made according to the methods described herein and iPS cell compositions comprising an iPS cell in an admixture with a TGF?R inhibitor. Further described herein are kits for producing iPS cells using a TGF?R inhibitor.
    Type: Grant
    Filed: August 25, 2009
    Date of Patent: October 30, 2012
    Assignee: The General Hospital Corporation
    Inventors: Konrad Hochedlinger, Matthias Stadtfeld